• Skip to primary navigation
  • Skip to main content
SRI logo
  • About
    • Press room
    • Our history
  • Expertise
    • Advanced imaging systems
    • Artificial intelligence
    • Biomedical R&D services
    • Biomedical sciences
    • Computer vision
    • Cyber & formal methods
    • Education and learning
    • Innovation strategy and policy
    • National security
    • Ocean & space
    • Quantum
    • Robotics, sensors & devices
    • Speech & natural language
    • Video test & measurement
  • Ventures
  • NSIC
  • Careers
  • Contact
  • 日本支社
Search
Close
Home » Archives for Carol Green
Carol Green

Carol Green

Senior Director, Preclinical Development
Go to bio page

Publications

Biomedical sciences publications March 21, 2022

A tandem liquid chromatography and tandem mass spectrometry (LC/LC–MS/MS) technique to separate and quantify steroid isomers 11β-methyl-19-nortestosterone and testosterone 

Carol Green

Here we describe a high-sensitivity LC/LC-MS/MS method that combines chiral chromatography and reverse-phase chromatography.

Biomedical sciences publications March 1, 2022

Pharmacokinetics and Safety Studies in Rodent Models Support Development of EPICERTIN as a Novel Topical Wound-Healing Biologic for Ulcerative Colitis 

Carol Green

This study established for the first time the pharmacokinetics, bioavailability, and acute safety of EPICERTIN in healthy and dextran sodium sulfate-induced colitic mice and healthy rats.

Biomedical sciences publications February 8, 2022

Enhancement of sensitivity and quantification quality in the LC-MS/MS measurement of large biomolecules with sum of MRM (SMRM)

Carol Green, Jon C. Mirsalis

We describe here an approach to boost detection sensitivity and expand dynamic range in the quantitation of large molecules while maintaining analytical specificity using summation of MRM (SMRM) transitions and LC separation technique.

Biomedical sciences publications March 1, 2015

Formulation Approaches to Improving the Delivery of an Antiviral Drug with Activity against Seasonal Flu

Shravan K Mutyam, Carol Green, Gita Shankar

The main objective of the present study was to develop formulations of noscapine hydrochloride hydrate with enhanced solubility and bioavailability using co-solvent- and cyclodextrin-based approaches.

Biomedical sciences publications March 1, 2015

Pharmacokinetics and Metabolism of 4R-Cembranoid

Carol Green

The purpose of this study was to examine the metabolism and pharmacokinetics of 4R as part of its preclinical development as a neuroprotective drug.

Biomedical sciences publications February 1, 2015

Nitrocobinamide, a New Cyanide Antidote That Can Be Administered by Intramuscular Injection

Carol Green

Here we show that adding sodium nitrite to cobinamide yields a stable derivative that rescues cyanide-poisoned mice and rabbits when given by intramuscular injection.

Biomedical sciences publications August 1, 2014

Cyanide Detoxification by Molybdenum Sulfur Complexes

Carol Green

Biomedical sciences publications August 1, 2014 Conference Paper

Development of an Agonist of the TGF-Beta Signaling Pathway to Treat Alzheimer’s Disease

Carol Green

Alzheimer’s disease (AD) is a neurodegenerative disorder that leads to progressive cognitive dysfunction. Current knowledge of the processes leading to AD is still limited, and no effective treatments are available. Because neurodegeneration is associated with injury and activation of innate immune responses in the brain, drugs that could mimic the beneficial aspects of this response are potential therapeutic candidates. The cytokine transforming growth factor (TGF)-?1 is an organizer of the brain’s response to injury and has been shown to have neuroprotective effects in models of brain injury and degeneration. Recombinant TGF-?1 has been used to treat various forms of brain injury in vivo but delivery is not suitable for human use. Studies from our lab have demonstrated that TGF-?1 can reduce the overall accumulation of A?, a key factor in AD pathogenesis, in mouse models for AD and in cell culture. Numerous studies have also demonstrated that TGF-?1 is a potent neurotrophic factor, although high-level chronic TGF-?1 production can also be detrimental. Recently, we reported that reduced TGF-?1 expression in vivo or in cultured neurons increases neurodegeneration. Additional studies show that reducing TGF-? signaling in neurons of a mouse model for AD increases A? accumulation and neurodegeneration and that TGF-? receptor expression is reduced in human AD brains. We have identified bioactive small molecule chemical compounds that can activate the TGF-? signaling pathway in hippocampal neurons of mice and that pass the blood-brain barrier. With reporter cell lines for the TGF-? signaling pathway we screened a diverse small molecule drug library and identified several compounds that are able to activate the reporter system in vitro and in TGF-? reporter mice in vivo. The compounds induce specific TGF-?-responsive genes in cell culture consistent with Smad dependent activation of the TGF-? pathway. These chemicals share common properties from which we propose here to derive a lead compound within 5 years. This project includes structure activity relationship analysis of identified active compounds, medicinal chemistry, toxicology and pharmacology in a subcontract with SRI International. Compounds will be tested in neuroprotection and neurotoxicity assays in cell culture and in TGF-? reporter mice in vivo. The two most promising compounds will then be tested in an in vivo model of neurodegeneration and in a mouse model for AD. Part of the in vivo analysis on neurodegeneration will be done in collaboration with researchers at UCSD. At the end of our studies we propose to have for the first time a novel neuroprotective and amyloid reducing investigational new drug based on the TGF-? signaling pathway for testing in patients with AD.

Biomedical sciences publications February 1, 2014

Evaluating the Toxicity of Novel Zn-DTPA Tablet Formulation in Dogs and Rats

Gita Shankar, Carol Green

The purpose of this research work is to evaluate toxicity of diethylenetriamine pentaacetic acid zinc trisodium salt (Zn-DTPA) tablets.

  • Go to page 1
  • Go to page 2
  • Go to Next Page »

How can we help?

Once you hit send…

We’ll match your inquiry to the person who can best help you.

Expect a response within 48 hours.

Career call to action image

Make your own mark.

Search jobs

Our work

Case studies

Publications

Timeline of innovation

Areas of expertise

Institute

Leadership

Press room

Media inquiries

Compliance

Careers

Job listings

Contact

SRI Ventures

Our locations

Headquarters

333 Ravenswood Ave
Menlo Park, CA 94025 USA

+1 (650) 859-2000

Subscribe to our newsletter


日本支社
SRI International
  • Contact us
  • Privacy Policy
  • Cookies
  • DMCA
  • Copyright © 2023 SRI International
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}